Joshua A. Bauer

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

Brian D. Lehmann, Joshua A. Bauer, Xi Chen et al. · Journal of Clinical Investigation · 2011 · 5.5K citations · Full text

Medicine, Oncology, Pharmacology +17

EGFR, p16, HPV Titer, Bcl-xL and p53, Sex, and Smoking As Indicators of Response to Therapy and Survival in Oropharyngeal Cancer

Bhavna Kumar, Kitrina G. Cordell, Julia S. Lee et al. · Journal of Clinical Oncology · 2008 · 614 citations · Full text

Medicine, Oncology, Chemotherapy +13

Molecular Profiling of the Residual Disease of Triple-Negative Breast Cancers after Neoadjuvant Chemotherapy Identifies Actionable Therapeutic Targets

Justin M. Balko, Jennifer M. Giltnane, Kai Wang et al. · Cancer Discovery · 2013 · 477 citations · Full text

Medicine, Cancer Biology, Oncology +17

Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer

Luigi Formisano, Yao Lu, Alberto Servetto et al. · Nature Communications · 2019 · 419 citations · Full text

Medicine, Oncology, Pharmacology +17

PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors

Brian D. Lehmann, Joshua A. Bauer, Johanna M. Schafer et al. · Breast Cancer Research · 2014 · 331 citations · Full text

Medicine, Cancer Biology, Oncology +16